Showing results (121-130 of 140) with videos related to
Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|September 14, 2018
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinomaJhanelle E Gray, Alberto Chiappori, Charlie C Williams, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung CancerAlberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2012
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsD Neil Hayes, Amy S Lucas, Tawee Tanvetyanon, et al.Journal of Oncology Practice|March 2, 2012
Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in FloridaTawee Tanvetyanon, Michelle Corman, Ji-Hyun Lee, et al.Clinical Lung Cancer|January 16, 2026
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab UseUtsav Joshi, Faustine Ong, Daniel Melzer, et al.International Journal of Radiation Oncology, Biology, Physics|October 1, 2020
Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung CancerBradford A Perez, Sungjune Kim, Minhsuan Wang, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in OncologyPeter G Shields, Roy S Herbst, Douglas Arenberg, et al.International Journal of Radiation Oncology, Biology, Physics|January 19, 2023
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey L Liveringhouse, Kujtim Latifi, Amalin G Asous, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)Xiuning Le, Jyoti D Patel, Elaine Shum, et al.Nature Medicine|August 13, 2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trialBenjamin C Creelan, Chao Wang, Jamie K Teer, et al.Pageof 14